Consumer Reports Negative on Teva Pharma (TEVA), Mylan (MYL) Deal

Consumer Reports is out negative on the potential deal between Mylan (Nasdaq: MYL) and Teva Pharma (NYSE: TEVA).

In part, the report notes that the deal could hand consumers higher prices for generic and specialty drugs.

Teva and Mylan are both trading at or near session lows on Friday.

You May Also Be Interested In

• Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
• Can Schneider do a deal for Bentley? Citi discusses
• Glacier Bancorp (GBCI) Approved to Acquire Six Montana Branches From HTLF Bank (HTLF)